TVTXTravere Therapeutics Inc
TVTX
Travere Therapeutics Inc1,499
Mkt Cap
$4.04BVolume
217,517.0052W High
$48.6152W Low
$13.88PE Ratio
-83.66TVTX Fundamentals
Price
$44.63Prev Close
$44.74Open
$44.5850D MA
$36.36Beta
1.49Avg. Volume
2.72MEPS (Annual)
-$0.5634P/B
41.87Rev/Employee
$987,380.28$3,414.72
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800...
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare...
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the Notes...
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Wells Fargo & Company upped their price objective on shares of Travere Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday...
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the Notes) in an underwritten offering. Travere also expects to grant the underwriters of the Notes...
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.read more...
TD Cowen Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $60.00
TD Cowen increased their price target on shares of Travere Therapeutics from $45.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday...
Travere Therapeutics Q1 Earnings Call Highlights
Travere Therapeutics (NASDAQ:TVTX) executives highlighted a first-quarter marked by an FDA approval, record demand for FILSPARI in IgA nephropathy, and renewed progress in the company's late-stage pipeline, according to remarks on the company's first quarter 2026 financial results call.
FDA approva...
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>
Compact View
Not available
Not available